Author

M. Arıcı

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Finerenone Use in Heart Failure Patients with Type 2 Diabetes and Kidney Disease: An Analysis of the FINE-TURK Registry.

BACKGROUND Finerenone, a non-steroidal mineralocorticoid receptor antagonist, improves cardiorenal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. However, real-world data on its use in patients with concomitant heart failure remain limited. This study aimed to evaluate the baseline chara...

Serap Yadigar, Suat Akgür, T. Güvenç et al. · Cardiovascular Drugs and The... · 0 citations

Open access Jan 2026

Uncontrolled Hypertension in Cardio‐Renal‐Metabolic Diseases: Real‐World Insights on Patient Profiles and Management Patterns From iCaReMe Global Registry

Background Hypertension (HTN) is a leading risk factor for cardiovascular (CV) and renal morbidity and mortality, yet blood pressure (BP) control remains suboptimal worldwide. Understanding management patterns, especially among patients with coexisting Type 2 diabetes mellitus (T2DM), chronic kidney diseases (CKDs), or...

K. Khunti, M. Arıcı, Carol A. Pollock et al. · International Journal of Hyp... · 0 citations

Review Open access Sep 2026

Features of Lipid Disorders in Cardiovascular–Kidney–Metabolic Syndrome

Cardiovascular–kidney–metabolic (CKM) syndrome is driven by the interplay of visceral adiposity, insulin resistance, chronic inflammation, oxidative stress, and progressive kidney dysfunction. These mechanisms generate a distinct atherogenic dyslipidaemic phenotype characterised by elevated triglycerides (TG), reduced...

A. Ceasovschih, Y. Şener, M. Arıcı et al. · International Journal of Mol... · 0 citations